3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
545
Lymphoma
444
Precursor Cell Lymphoblastic Leukemia-Lymphoma
409
Lymphoma, Large B-Cell, Diffuse
347
Leukemia
344
Multiple Myeloma
335
Lymphoma, Non-Hodgkin
316
Leukemia, Myeloid, Acute
288
Leukemia, Lymphocytic, Chronic, B-Cell
285
Lymphoma, Follicular
240
Burkitt Lymphoma
217
Myelodysplastic Syndromes
209
Lymphoma, Mantle-Cell
201
Hodgkin Disease
193
Recurrence
153
Lymphoma, B-Cell, Marginal Zone
142
Melanoma
135
Lymphoma, Large-Cell, Immunoblastic
116
Neoplasms
109
Lymphoma, B-Cell
103
Neuroblastoma
101
Neoplasms, Plasma Cell
99
Ovarian Neoplasms
96
Triple Negative Breast Neoplasms
93
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
91
Myeloproliferative Disorders
87
Hematologic Neoplasms
87
Leukemia, Myeloid, Chronic-Phase
83
Leukemia, Myeloid, Accelerated Phase
80
Leukemia, Myelomonocytic, Chronic
78
Interventions
Imatinib Mesylate
67
Sunitinib
27
nilotinib
14
regorafenib
13
ripretinib
10
avapritinib
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
Laparoscopy
4
CTLA-4 Antigen
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
trametinib
2
tanespimycin
2
ponatinib
2
pembrolizumab
2
masitinib
2
famitinib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Stromal Tumors
×
Cyclophosphamide
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled